v3.25.2
Product Revenue
 6 Months Ended
Jun. 30, 2025
Revenue from Contract with Customer [Abstract]  
Product Revenue Product Revenue
The Company’s product revenue is primarily derived from the sale of its internally developed products BRUKINSA® and TEVIMBRA® in the U.S., China, EU, and other regions; XGEVA®, BLINCYTO® and KYPROLIS® in China under a license from Amgen; and POBEVCY® in China under a license from Bio-Thera.
The table below presents the Company’s net product revenue for the three and six months ended June 30, 2025 and 2024.
 Three Months EndedSix Months Ended
 June 30,June 30,
 2025202420252024
 $$$$
Product revenue – gross1,657,838 1,167,155 3,057,904 2,111,619 
Less: Rebates and sales returns(355,762)(246,009)(647,298)(443,555)
Product revenue – net1,302,076 921,146 2,410,606 1,668,064 
The following table disaggregates net product revenue by product for the three and six months ended June 30, 2025 and 2024:
 Three Months EndedSix Months Ended
 June 30,June 30,
 2025202420252024
 $$$$
BRUKINSA®
949,840 637,399 1,741,504 1,125,914 
TEVIMBRA®
193,524 158,410 364,688 303,687 
XGEVA®
81,318 55,054 151,741 98,435 
BLINCYTO®
25,587 19,131 49,493 33,497 
KYPROLIS®
19,416 15,936 39,144 30,047 
POBEVCY®
11,242 11,572 24,987 28,205 
Other21,149 23,644 39,049 48,279 
Total product revenue – net1,302,076 921,146 2,410,606 1,668,064 
The following table presents the roll-forward of accrued revenue rebates and returns for the six months ended June 30, 2025 and 2024:
 Rebates, Returns and Other DeductionsContra AR AccrualsTotal
 $$
Balance at December 31, 2024235,600 50,699 286,299 
Accrual283,525 363,773 647,298 
Payments(221,808)(361,633)(583,441)
Balance at June 30, 2025297,317 52,839 350,156 
Balance at December 31, 2023139,936 30,435 170,371 
Accrual222,179 221,376 443,555 
Payments(188,852)(209,450)(398,302)
Balance at June 30, 2024173,263 42,361 215,624